STOCK TITAN

Travere Therapeutics to Participate at Upcoming Investor Conferences

Travere Therapeutics (TVTX) management will participate in upcoming investor conferences, beginning with the Guggenheim Global Healthcare Conference on November 10, 2026.

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences:

Guggenheim Global Healthcare Conference
Presenting on Tuesday, November 10, 2026, at 8:00 a.m. ET

Stifel 2026 Healthcare Conference
Presenting on Wednesday, November 11, 2026, at 3:20 p.m. ET

UBS Global Biopharma Conference
Presenting on Monday, November 16, 2026, at 11:20 a.m. GMT

Jefferies London Healthcare Conference
Presenting on Tuesday, November 17, 2026, at 8:00 a.m. GMT

Live webcasts of the presentations will be accessible on the Investor page of Travere’s website at ir.travere.com/events-and-presentations. Replays will be available for up to 30 days following each event.

About Travere Therapeutics

At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.

Investors:
888-969-7879
ir@travere.com

Media:
888-969-7879
mediarelations@travere.com

Source: Travere Therapeutics, Inc.

Keep reading